It has been shown that the absence of IL-33 in experimental models results in decreased GVHD severity through a mechanism that involves the suppression of TNFa release, and this phenomenon is inverted when IL-33 is administered followed by an increase in the number of effector T cells. Here, IL33 is linked to graft versus host disease.